title: Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis.
abstract: The results of this study provide the first evidence that two completely separate vaccine approaches, one based on a subunit vaccine consisting of a mild adjuvant admixed with purified culture filtrate proteins and enhanced by the cytokine interleukin-2 and the second based on immunization with DNA encoding the Ag85A protein secreted by Mycobacterium tuberculosis, could both prevent the onset of caseating disease, which is the hallmark of the guinea pig aerogenic infection model. In both cases, however, the survival of vaccinated guinea pigs was shorter than that conferred by Mycobacterium bovis BCG, with observed mortality of these animals probably due to consolidation of lung tissues by lymphocytic granulomas. An additional characteristic of these approaches was that neither induced skin test reactivity to commercial tuberculin. These data thus provide optimism that development of nonliving vaccines which can generate long-lived immunity approaching that conferred by the BCG vaccine is a feasible goal.
authors.affiliation: Mycobacteria Research Laboratories, Department of Microbiology, Colorado State University, Fort Collins, Colorado 80523, USA.
authors.forename: S L
authors.initials: SL
authors.lastname: Baldwin
authors.forename: C
authors.initials: C
authors.lastname: D'Souza
authors.forename: A D
authors.initials: AD
authors.lastname: Roberts
authors.forename: B P
authors.initials: BP
authors.lastname: Kelly
authors.forename: A A
authors.initials: AA
authors.lastname: Frank
authors.forename: M A
authors.initials: MA
authors.lastname: Lui
authors.forename: J B
authors.initials: JB
authors.lastname: Ulmer
authors.forename: K
authors.initials: K
authors.lastname: Huygen
authors.forename: D M
authors.initials: DM
authors.lastname: McMurray
authors.forename: I M
authors.initials: IM
authors.lastname: Orme
mesh_terms: D000217:Acyltransferases; D000818:Animals; D000942:Antigens, Bacterial / Q000627:therapeutic use; D001500:BCG Vaccine / Q000627:therapeutic use*; D001426:Bacterial Proteins / Q000627:therapeutic use; D004195:Disease Models, Animal; D005069:Evaluation Studies as Topic; D005260:Female; D006168:Guinea Pigs; D006968:Hypersensitivity, Delayed; D007376:Interleukin-2 / Q000627:therapeutic use; D008050:Lipid A / Q000031:analogs & derivatives / Q000627:therapeutic use; D008168:Lung / Q000473:pathology; D051379:Mice; D014397:Tuberculosis, Pulmonary / Q000401:mortality / Q000517:prevention & control*; D014611:Vaccination; D019444:Vaccines, DNA / Q000627:therapeutic use
chemical_list: D000942:Antigens, Bacterial; D001500:BCG Vaccine; D001426:Bacterial Proteins; D007376:Interleukin-2; D008050:Lipid A; D019444:Vaccines, DNA; D000217:Acyltransferases; C112580:antigen 85A, Mycobacterium tuberculosis; C048436:monophosphoryl lipid A